Last reviewed · How we verify
vectibix
At a glance
| Generic name | vectibix |
|---|---|
| Sponsor | Centre Jean Perrin |
| Target | Epidermal growth factor receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Secondary malignant neoplasm of colon
Common side effects
- Skin rash with variable presentations
- Dermatologic toxicities
- Paronychia
- Fatigue
- Nausea
- Diarrhea
- Pyrexia
- Ocular toxicities
- Conjunctivitis
- Dry mouth
- Epistaxis
- Pustular rash
Serious adverse events
- Severe dermatologic toxicity (Grade 3+)
- General physical health deterioration
- Intestinal obstruction
- Severe paronychia
- Mucosal inflammation (Grade 3)
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation (PHASE2)
- Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) (PHASE2)
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures (EARLY_PHASE1)
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors (PHASE1)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vectibix CI brief — competitive landscape report
- vectibix updates RSS · CI watch RSS
- Centre Jean Perrin portfolio CI